


Bromperidol hydrochloride

Cat. No.:	HY-B0901A
CAS No.:	59453-24-6
Molecular Formula:	C ₂₁ H ₂₄ BrClFNO ₂
Molecular Weight:	456.78
Target:	Dopamine Receptor; Bacterial
Pathway:	GPCR/G Protein; Neuronal Signaling; Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : ≥ 100 mg/mL (218.92 mM) * "≥" means soluble, but saturation unknown.					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		2.1892 mL	10.9462 mL	21.8924 mL
		5 mM		0.4378 mL	2.1892 mL	4.3785 mL
10 mM		0.2189 mL	1.0946 mL	2.1892 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Bromperidol (R-11333) hydrochloride possesses antipsychotic activity, with a high affinity for central dopamine receptors D ₂ . Bromperidol hydrochloride can kill Mycobacteria in a synergistic manner with Spectinomycin ^{[1][2]} .
IC₅₀ & Target	D ₂ Receptor
In Vivo	Bromperidol hydrochloride antagonises stereotyped behaviour and agitation induced by apomorphine or amphetamine, and inhibits conditioned reactions and learned intracranial self-stimulation in rats ^[1] . Bromperidol hydrochloride antagonises apomorphine-induced emesis and inhibits the conditioned avoidance response in dogs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Biol Pharm Bull. 2021;44(8):1140-1150.
- Pharmacology. 2019 May 8;104(1-2):43-50.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Benfield P, et al. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. *Drugs*. 1988 Jun;35(6):670-84.
- [2]. Ramón-García S, et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. *Antimicrob Agents Chemother*. 2011 Aug;55(8):3861-9.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA